Kodiak Sciences (KOD)
(Delayed Data from NSDQ)
$2.48 USD
-0.16 (-6.06%)
Updated Aug 29, 2024 04:00 PM ET
Pre-Market: $2.58 +0.10 (4.03%) 8:18 AM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Kodiak Sciences Inc. (KOD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.25 | $5.00 | $2.00 | 31.05% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Kodiak Sciences Inc. comes to $3.25. The forecasts range from a low of $2.00 to a high of $5.00. The average price target represents an increase of 31.05% from the last closing price of $2.48.
Analyst Price Targets (4 )
Broker Rating
Kodiak Sciences Inc. currently has an average brokerage recommendation (ABR) of 4.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 4.00 a month ago based on six recommendations.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/KOD.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 3 | 3 | 3 | 3 | 3 |
ABR | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Not Identified | Not Identified | Hold | Hold |
4/4/2024 | UBS | Eliana Merle | Hold | Hold |
4/1/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
3/1/2024 | Chardan Capital Markets | Daniil Gataulin | Hold | Hold |
12/11/2023 | Goldman Sachs | Andrea Tan | Not Available | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 4.00 |
ABR (Last week) | 4.00 |
# of Recs in ABR | 6 |
Average Target Price | $3.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.90 |